Premium
Association between eIF3α polymorphism and severe toxicity caused by platinum‐based chemotherapy in non‐small cell lung cancer patients
Author(s) -
Xu Xiaojing,
Han Lifang,
Duan Li,
Zhao Yingchun,
Yang Huaping,
Zhou Boting,
Ma Rui,
Yuan Ruixia,
Zhou Honghao,
Liu Zhaoqian
Publication year - 2013
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2012.04379.x
Subject(s) - lung cancer , cisplatin , toxicity , chemotherapy , oncology , medicine , nephrotoxicity , single nucleotide polymorphism , carboplatin , biology , genotype , gene , genetics
Aim Platinum‐induced toxicity severely impedes successful chemotherapy in lung cancer patients. The nucleotide excision repair ( NER ) pathway is considered as one of the major factors contributing to platinum effects. Furthermore, genetic variances of the NER pathway influence platinum toxicity. eIF3α , over expressed in many malignancies, is an up‐stream gene of NER and could regulate its activity. The purpose of this study was to investigate whether eIF3α polymorphism is associated with severe platinum toxicity in patients with non‐small cell lung cancer ( NSCLC ). Methods Two hundred and eighty‐two incident NSCLC patients, from three different institutions, were enrolled and followed up. These patients were diagnosed and histologically confirmed with non‐small cell lung cancer. All patients accepted platinum based chemotherapy for at least two cycles. Twenty‐two SNPs of eIF3α were detected in these patients. Results eIF3α A rg803 L ys C > T polymorphism was associated with cisplatin‐induced toxicity in NSCLC patients ( P = 0.02, OR = 0.54, 95% CI 0.32, 93). T‐carrier subjects presented better tolerance to platinum nephrotoxicity, but poorer tolerance to ototoxicity. Conclusion eIF3α Arg803Lys was associated with platinum toxicity in NSCLC patients and could be considered as a predictor for pretreatment evaluation in lung cancer patients.